Not Medicare Enrolled

Dr. Dilip Solanki, MD

Medical Oncology · Dallas, TX
Consulting-driven
3555 W WHEATLAND RD, Dallas, TX 75237
9727092580
In practice since 2006 (19 years)
NPI: 1124060116 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 2 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Solanki from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Solanki? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Solanki

Dr. Dilip Solanki is a medical oncology specialist in Dallas, TX, with 19 years of NPI registration.

Between the years covered by Open Payments, Dr. Solanki received a total of $42,463 from 49 pharmaceutical and/or device companies across 243 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Solanki is Moderate — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice $42,463 industry payments

Industry Payment Transparency

Open Payments through 2023 ↗
$42,463
Total received (2018-2023)
Avg $7,077/year across 6 years
Top 23% in TX for medical oncology
49
Companies
243
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$22,622 (53.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12,135 (28.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,706 (18.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2023
$248
2022
$233
2021
$672
2020
$349
2019
$14,644
2018
$26,318

Payments by company (2023)

Consulting
Speaking
Meals & Travel
Research
Takeda Pharmaceuticals U.S.A., Inc.
$10,482
AbbVie, Inc.
$5,158
EISAI INC.
$4,906
Kyowa Kirin, Inc.
$4,857
TESARO, Inc.
$3,292
Seattle Genetics, Inc.
$2,839
AstraZeneca Pharmaceuticals LP
$2,511
Ipsen Biopharmaceuticals, Inc
$1,468
Merck Sharp & Dohme Corporation
$758
E.R. Squibb & Sons, L.L.C.
$543
Astellas Pharma US Inc
$526
Janssen Biotech, Inc.
$443
PFIZER INC.
$441
Genentech USA, Inc.
$367
Regeneron Healthcare Solutions, Inc.
$352
Incyte Corporation
$324
Puma Biotechnology, Inc.
$241
Rigel Pharmaceuticals, Inc.
$184
Bayer HealthCare Pharmaceuticals Inc.
$165
Alexion Pharmaceuticals, Inc.
$152
Taiho Oncology, Inc.
$151
GENZYME CORPORATION
$149
Clovis Oncology, Inc.
$144
Gilead Sciences, Inc.
$140
Array BioPharma Inc.
$132
Pharmacyclics LLC, An AbbVie Company
$129
Novartis Pharmaceuticals Corporation
$126
Helsinn Therapeutics (U.S.), Inc.
$124
AbbVie Inc.
$123
Karyopharm Therapeutics Inc.
$121
Jazz Pharmaceuticals Inc.
$120
PUMA BIOTECHNOLOGY, INC.
$119
GlaxoSmithKline, LLC.
$111
Heron Therapeutics, Inc.
$110
Celgene Corporation
$109
Janssen Scientific Affairs, LLC
$107
COMSORT, Inc
$100
JAZZ PHARMACEUTICALS INC.
$87
Exelixis Inc.
$61
Amgen Inc.
$38
Analogic Corporation
$38
Janssen Pharmaceuticals, Inc
$32
Lilly USA, LLC
$14
Boehringer Ingelheim Pharmaceuticals, Inc.
$13
TerSera Therapeutics LLC
$13
EMD Serono, Inc.
$12
Teva Pharmaceuticals USA, Inc.
$11
Sirtex Medical Inc
$10
MEDIVATION FIELD SOLUTIONS LLC
$9
Top 3 companies account for 48.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · Alecensa · Avastin · BENDEKA · BOSULIF · Bavencio · Braftovi · CABLIVI · CALQUENCE · CHANTIX · CINVANTI · CYRAMZA · Cabometyx · DARZALEX · ELIQUIS · EMEND · EMPLICITI · ERLEADA · Erleada · FASLODEX · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INREBIC · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LYNPARZA · Lenvima · Lonsurf · NERLYNX · NINLARO · Nerlynx · Neulasta · OPDIVO · Onivyde · POTELIGEO · Rubraca · SANCUSO · SARCLISA · SIR-Spheres Microspheres · SOLIRIS · SUTENT · TAGRISSO · TALZENNA · TECENTRIQ · Tavalisse · Trodelvy · ULTOMIRIS · VELCADE · VENCLEXTA · VYXEOS · Venclexta · Vitrakvi · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xofigo · ZEJULA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (53%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Looking for a medical oncology specialist in Dallas?
Compare medical oncologists in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
81
Per 100K population
3.1
County median income
$74,149
Nearest hospital
METHODIST CHARLTON MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment — Not enrolled N/A
Practice Data — No data N/A
Industry Payments ✓ Open Payments CY 2023
Disciplinary History — Not public N/A

This provider has data in 2 of 4 available federal datasets, with a Data Coverage level of Moderate. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Solanki is a medical oncology specialist, with consulting-driven industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Solanki receive payments from pharmaceutical companies?
Yes. Dr. Solanki received a total of $42,463 from 49 companies across 243 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. Solanki) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Medical Oncologists in Dallas
Browse medical oncologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
AbbVie, Inc. Payments to Doctors
See all physicians who received payments from AbbVie, Inc.
By company
EISAI INC. Payments to Doctors
See all physicians who received payments from EISAI INC.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →